智通财经网·2025-09-26 06:58Core Viewpoint - The global small nucleic acid drug market is experiencing significant growth, with a projected increase from $4.6 billion in 2023 to $46.7 billion by 2033, driven by technological advancements and increased clinical approvals [1][2]. Market Growth - The global small nucleic acid drug market size grew from $2.7 billion in 2019 to $4.6 billion in 2023, reflecting a compound annual growth rate (CAGR) of 14.3% [2]. - The market is expected to accelerate growth starting in 2023, with a projected CAGR of 26.1% until it reaches $46.7 billion by 2033 [1][2]. Technological Advancements - Small nucleic acid drugs are becoming more mature, offering significant advantages over traditional small molecule and antibody drugs, including shorter development cycles, a wider range of targets, lasting effects, and higher success rates [1][3]. - These drugs act directly on the mRNA level, targeting "undruggable" targets that traditional drugs cannot reach, providing new treatment options for many difficult-to-treat diseases [1]. Shift in Focus - The trend is shifting from rare diseases to chronic and common diseases, with small nucleic acid drugs expanding into areas such as hyperlipidemia, hepatitis B, and hypertension [2][3]. - Currently, there are 22 approved small nucleic acid drugs globally, primarily focused on rare diseases, but recent data indicates a move towards more prevalent conditions [2]. Domestic Market Dynamics - Domestic innovative pharmaceutical companies are accelerating their entry into the small nucleic acid drug market, focusing on chronic diseases rather than following the traditional model of starting with rare diseases [3]. - Key therapeutic areas for domestic companies include cardiovascular diseases, hepatitis B, and cancer [3]. Investment Opportunities - Companies with proprietary technology platforms and advantageous pipelines are recommended for investment, including Reebio, Sanofi, Bowang Pharmaceutical, Yuyuan Pharmaceutical, CSPC Pharmaceutical, Tsinghua Tongfang, and Hengrui Medicine [4]. - Notable overseas companies include Alnylam, Ionis, and Arrowhead [4].